A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients

Trial Profile

A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Dec 2016

At a glance

  • Drugs Guadecitabine (Primary) ; Irinotecan; Regorafenib; Tipiracil/trifluridine
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 08 Jun 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 20 Apr 2016 Interim results (n=22) presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top